Business Wire

Fujitec Switches to Rimini Street for Oracle Database Support

Jaa

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products, today announced that Fujitec Co., Ltd., a leading manufacturer of elevators and escalators, has switched to Rimini Street support for its Oracle Database software. By switching to Rimini Street, Fujitec immediately realized savings of 50 percent from what they had been paying Oracle for annual support fees, and they are also receiving Rimini Street’s more comprehensive, responsive support. Under Rimini Street support, Fujitec can continue to run its robust, stable Oracle Database 10.2 and 11.2 releases for a guaranteed minimum of 15 additional years without a required upgrade just to stay supported. Fujitec has also been able to free up vital resources from database maintenance that can be reinvested into important IT initiatives, including virtual reality and mobile applications, as well as an ongoing project to migrate systems to a new private cloud infrastructure.

This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171030006193/en/

Fujitec Switches to Rimini Street for Oracle Database Support (Photo: Business Wire)

Fujitec Switches to Rimini Street for Oracle Database Support (Photo: Business Wire)

Reduced IT Costs, Enhanced Productivity

In recent years, Fujitec’s strategy has been focused on reducing IT operating costs and delivering enhanced productivity. As part of this strategy, the company began migrating much of its IT infrastructure to a private cloud. Even with the migration to a more cost-effective private cloud infrastructure, the organization was incurring too high a cost for annual support fees and labor to maintain and operate its large scale, core database environment. These costs included a significant amount of effort devoted to self-support, primarily because Oracle was not providing the support services Fujitec needed. Oracle’s expensive annual fees, service deficiencies and excessive labor requirements led Fujitec to explore options that would reduce annual support costs, meet its support service needs as well as receive better quality support. Fujitec selected Rimini Street’s annual support to meet its objectives.

“When evaluating our overall IT budget, it was clear that Oracle’s annual maintenance and related costs for our Oracle Database landscape was a significant spend. When we evaluated Rimini Street support services, it became the obvious choice for us. We benefited from the immediate 50 percent reduction in our annual maintenance fees, labor savings from not having to perform release upgrades and additionally, we are now receiving more responsive and comprehensive support than what we had been receiving from Oracle,” said Kenji Tomooka, chief information officer, Information System Department, Fujitec Co. “With the cost savings realized by switching to Rimini Street, we have been able to fund other innovative IT projects. Our company has been successful migrating much of our IT infrastructure to the cloud and continuing our transformation toward a digital enterprise, while being able to keep applications we develop in-house on our core Oracle Database landscape.”

New Unparalleled Support

When evaluating their support and maintenance needs, Fujitec wanted the ability to work directly with expert engineers who could deliver more responsive service and a faster time to resolution. As with all Rimini Street clients, Fujitec now has an assigned senior level Primary Support Engineer (PSE) with at least 10 years’ experience with Oracle Database software, and is experiencing a superior service experience compared to the call-center support model they had experienced with Oracle annual support. Rimini Street PSE’s are available 24/7/365 to address any support issues, and all clients receive the Company’s industry-leading SLA guaranteeing a 15-minute response time for critical cases.

“Direct interaction with an assigned Rimini Street Primary Support Engineer appealed to us the most. Previously, we would submit a ticket with the vendor, and frequently there would be multiple support personnel involved, many junior level, and it was not clear who was responsible for providing the solution,” continued Tomooka. “With Rimini Street, all engineers, led by our Primary Support Engineer, work together until the problem is solved to our satisfaction. We did not have the sense of security with Oracle that comes from such a collaborative environment we have found with Rimini Street. Personally, this is my first experience to have partnered with a company where all employees are fully committed to moving our business forward, and I am impressed with the expert engineers who work the same way we do.”

“Japan CIOs are being tasked with examining organizational growth strategies, increasing efficiencies and cultivating digital transformation, all while reducing overall costs,” said Yorio Wakisaka, general manager, North East Asia, Rimini Street. “By switching its Oracle Database support to Rimini Street, Fujitec has been able to reinvest their savings into strategic IT innovation initiatives, including enabling them to leverage a private cloud infrastructure. With Rimini Street’s proven, award-winning support, Fujitec, and all of our clients, know their current core systems of record are supported for a guaranteed minimum of 15 additional years from the date they move to Rimini Street.”

About Rimini Street, Inc.

Rimini Street, Inc. (Nasdaq: RMNI) is a global provider of enterprise software products and services, and the leading third-party support provider for Oracle and SAP software products. The company has redefined enterprise software support services since 2005 with an innovative, award-winning program that enables licensees of IBM, Microsoft, Oracle, SAP and other enterprise software vendors to save up to 90 percent on total support costs. Clients can remain on their current software release without any required upgrades for a minimum of 15 years. Over 1,330 global Fortune 500, midmarket, public sector and other organizations from a broad range of industries currently rely on Rimini Street as their trusted, third-party support provider. To learn more, please visit http://www.riministreet.com, follow @riministreet on Twitter and find Rimini Street on Facebook and LinkedIn. (C-RMNI)

Forward-Looking Statements

Certain statements included in this communication are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Forward-looking statements generally are accompanied by words such as “may,” “should,” “would,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “seem,” “seek,” “continue,” “future,” “will,” “expect,” “outlook” or other similar words, phrases or expressions. These forward-looking statements include, but are not limited to, statements regarding our industry, future events, as well as expected management, the estimated or anticipated future results and benefits of Rimini Street following the transaction, including the expected post-transaction ownership and cash and debt balances, future opportunities, estimates of Rimini Street’s total addressable market, and projections of customer savings. These statements are based on various assumptions and on the current expectations of management and are not predictions of actual performance, nor are these statements of historical facts. These statements are subject to a number of risks and uncertainties regarding Rimini Street’s business, and actual results may differ materially. These risks and uncertainties include, but are not limited to, changes in the business environment in which Rimini Street operates, including inflation and interest rates, and general financial, economic, regulatory and political conditions affecting the industry in which Rimini Street operates; adverse litigation developments; inability to refinance existing debt on favorable terms; changes in taxes, governmental laws, and regulations; competitive product and pricing activity; difficulties of managing growth profitably; the loss of one or more members of Rimini Street’s management team; failure to realize the anticipated benefits of the transaction, including difficulty in integrating the businesses of GPIAC and Rimini Street; uncertainty as to the long-term value of RMNI common stock; the inability to realize the expected amount and timing of cost savings and operating synergies; those discussed in GPIAC’s Annual Report on Form 10-K for the year ended December 31, 2016 under the heading “Risk Factors,” as updated from time to time by GPIAC’s and Rimini Street’s Quarterly Reports on Form 10-Q and other documents of GPIAC and Rimini Street on file with the Securities and Exchange Commission (“SEC”) or in the joint proxy statement/prospectus filed with the SEC by GPIAC. There may be additional risks that Rimini Street presently knows or that Rimini Street currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements provide Rimini Street’s expectations, plans or forecasts of future events and views as of the date of this communication. Rimini Street anticipates that subsequent events and developments will cause Rimini Street’s assessments to change. However, while Rimini Street may elect to update these forward-looking statements at some point in the future, Rimini Street specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Rimini Street's assessments as of any date subsequent to the date of this communication.

© 2017 Rimini Street, Inc. All rights reserved. “Rimini Street” is a registered trademark of Rimini Street, Inc. in the United States and other countries, and Rimini Street, the Rimini Street logo, and combinations thereof, and other marks marked by TM are trademarks of Rimini Street, Inc. All other trademarks remain the property of their respective owners, and unless otherwise specified, Rimini Street claims no affiliation, endorsement, or association with any such trademark holder or other companies referenced herein.

Contact information

Rimini Street, Inc.
Michelle McGlocklin, +1-925-523-8414
mmcglocklin@riministreet.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Login VSI Announces Free Meltdown/Spectre Emergency Edition17.1.2018 11:00Tiedote

Today software solution provider Login VSI (www.loginvsi.com), the industry leader in VDI and DaaS performance testing, announces the temporary availability of a free, full-production, license of their flagship product Login VSI to every organization using Citrix XenApp, Citrix XenDesktop, VMware Horizon, or Microsoft Remote Desktop Services (RDS). This Emergency Edition will be free for all end-user organizations looking to test the performance impact of Meltdown and Spectre security patches, and will be valid until March 31, 2018. This license offers unlimited users, unlimited locations and includes all standard workloads. This special license can be requested through the Login VSI website, and through selected partners in Login VSI’s extensive eco-system of (VDI-performance supporting) software, hardware and service vendors. Login VSI also started a series of lab tests to quantify the exact performance impact of the Meltdown and Spectre patches rolled out today, and will keep doing

Asuragen Obtains CE Mark of QuantideX® qPCR BCR-ABL Kits on Roche Diagnostics cobas z 480 Analyzer17.1.2018 11:00Tiedote

Asuragen, Inc., a global molecular diagnostics product company changing the way patients are treated in genetics and oncology by bringing complex molecular tests to hospital and reference labs, today announced that it has expanded its CE mark of the QuantideX® qPCR BCR-ABL IS Kit and QuantideX® qPCR BCR-ABL minor Kit to include clinical use on the Roche Diagnostics cobas z 480 Analyzer. The exquisite sensitivity and precision of the assays support clinicians in the rapidly evolving European clinical practice of therapy cessation for long-term responders on tyrosine kinase inhibitor (TKI) therapies. The available platforms, which also include the Applied Biosystems® 7500 Fast Dx Real-Time PCR instrument, improve the reach of the portfolio in Europe and Latin America. “As a global solutions provider, we are committed to ensuring that our best-in-class CML monitoring assays are widely available to deliver powerful answers that can impact patient decisions,” said Matthew McManus, M.D., Ph.

NTT Com Granted Microsoft's Gold Cloud Platform Status Globally17.1.2018 09:00Tiedote

NTT Communications Corporation (NTT Com), the ICT solutions and international communications business within the NTT Group (TOKYO:9432), is pleased to announce that it has been granted Microsoft Gold Cloud Platform status, the highest accreditation currently available, for its competency in delivering on quality, expertise and differentiated managed services in the cloud. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180116005911/en/ “Gold status is an important recognition of our competency in the cloud arena,” said Damian Skendrovic, CEO, NTT Com Managed Services. “With Microsoft Cloud Platform Competency we are helping enterprises to manage their hybrid cloud infrastructures, delivering on SaaS and PaaS solutions available in the Azure and Azure Stack marketplace that will enable our customers to optimize on performance and reach their business goals,” As part of its global strategy, NTT Com has been part of the early ado

Premas, IncellDx Ink India Distribution Agreement17.1.2018 08:01Tiedote

Premas Life Sciences Pvt., Ltd. and IncellDx, Inc. announced today they have signed an exclusive distribution agreement. The commercial partnership brings the power of cell by cell multiplex diagnostics for solid tumors carcinomas that can now be analyzed for molecular and protein biomarkers by flow cytometry. Included in the deal are: IncellDx's patented single-cell assays for quantifying PD-L1 on tumor cells and immune cell subtypes; patented single-cell assay for HPV E6, E7 mRNA detection in cervical samples; and, its incellPREP single-cell preparation kit for solid tissues including tumors. Researchers at AIIMS, New Delhi have completed a successful study utilizing IncellDx's next generation (3Dx) investigational molecular assay which quantifies E6, E7 mRNA overexpression in single cells simultaneously with the measurement of cell cycle and cell proliferation, the hallmark of progressive disease. Praveen Gupta, Managing Director of Premas Life Sciences commented: “India’s molecular

Ipsen and Exelixis announce phase 3 trial results of cabozantinib demonstrating significant overall survival benefit in patients with previously treated advanced hepatocellular carcinoma17.1.2018 01:05Tiedote

Regulatory News: Ipsen (Euronext:IPN; ADR:IPSEY) and Exelixis, Inc. (NASDAQ:EXEL) today announced detailed results of the pivotal phase 3 CELESTIAL trial in patients with previously treated advanced hepatocellular carcinoma (HCC), which will be presented in a late-breaking oral session at the 2018 ASCO-GI Symposium being held in San Francisco, January 18-20, 2018. In CELESTIAL, cabozantinib provided a statistically significant and clinically meaningful improvement versus placebo in overall survival (OS), the trial’s primary endpoint, at the planned second interim analysis (prespecified critical p value ≤ 0.021) for the population of second- and third-line patients enrolled in this study. Median OS was 10.2 months with cabozantinib versus 8.0 months with placebo (HR 0.76, 95 percent CI 0.63-0.92; p=0.0049). Median progression-free survival (PFS) was more than doubled, at 5.2 months with cabozantinib and 1.9 months with placebo (HR 0.44, 95 percent CI 0.36-0.52; p<0.0001). Objective resp

IFF to Release Fourth Quarter & Full Year 2017 Results February 1417.1.2018 00:15Tiedote

Regulatory News: International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF), a leading innovator of sensory experiences that move the world, announced that it will release its fourth quarter and full year 2017 earnings results following the market close on Wednesday, February 14, 2018. The management team will host a live webcast on Thursday, February 15, 2018 at 10:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at ir.iff.com. For those unable to listen to the live webcast, a recorded version will be made available for replay. Meet IFF International Flavors & Fragrances Inc. (NYSE:IFF) (Euronext Paris: IFF) is a leading innovator of sensorial experiences that move the world. At the heart of our company, we are fueled by a sense of discovery, constantly asking “what if?”. That passion for exploration drives us to co-create unique products that consumer

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme